Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P53673
UPID:
CRBA4_HUMAN
Alternative names:
Beta-A4 crystallin
Alternative UPACC:
P53673; Q4VB22; Q6ICE4
Background:
Beta-crystallin A4, also known as Beta-A4 crystallin, plays a pivotal role in the vertebrate eye lens, serving as a dominant structural component. This protein contributes to the clarity and refractive properties of the lens, essential for precise vision.
Therapeutic significance:
The mutation of Beta-crystallin A4 is linked to Cataract 23, multiple types, characterized by varying degrees of lens opacity, leading to visual impairment or blindness. Understanding the role of Beta-crystallin A4 could open doors to potential therapeutic strategies for cataract management and prevention.